MPLT 10-Q filed 2026-11-16 | Key takeaways
MPLT filed its 10-Q; the most relevant disclosure change is added August 2026 Private Placement: On August 13, 2026, the Company entered into a Securities Purchase Agreement with certain institutional investors and closed the 2026 Private Placement on August 14, 2026, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 s.
Key takeaways
August 2026 private placement raised $140.1M net proceeds; Catalyst purchased $83.4M and Forbion purchased $8.6M of the total $92M from related parties
Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia announced positive topline results in July 2026; FDA end-of-phase 2 meeting planned
Phase 2 IRIS trial for ML-004 in autism spectrum disorder did not meet primary endpoint in June 2026
Phase 2 VISTA trial for ML-007C-MA in Alzheimer's disease psychosis ongoing; topline results expected H2 2027
Cash, cash equivalents and investments of $463.4M as of September 30, 2026, versus $351.3M as of June 30, 2026
Accumulated deficit widened to $533.0M as of September 30, 2026, from $481.4M as of June 30, 2026
Vanderbilt Agreement amended in September 2026; one-time $0.4M payment made; aggregate milestone obligations revised to up to $52.0M
Key metrics
Disclosure changes
- August 2026 Private Placement
On August 13, 2026, the Company entered into a Securities Purchase Agreement with certain institutional investors and closed the 2026 Private Placement on August 14, 2026, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 shares for net proceeds of $140.1 million, after deducting $10.0 million in placement agent fees and offering expenses. Related parties Catalyst and Forbion participated, purchasing approximately $92.0 million of the offering. Registration rights agreement r...
Major equity financing that significantly increased cash position and provides runway through 2028; related party participation indicates insider confidence; dilution to existing shareholders. - Phase 2 Clinical Trial Results - ML-007C-MA Schizophrenia
In July 2026, the Company announced positive topline results from ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for treatment of schizophrenia. The Company intends to engage with FDA in an end-of-Phase 2 meeting to discuss the path forward, including design of a Phase 3 trial intended to support an initial NDA submission.
Positive Phase 2 results represent significant clinical milestone and path toward potential regulatory approval. - Phase 2 Clinical Trial Results - ML-004 ASD
In June 2026, the Company announced topline results from IRIS, a Phase 2 trial evaluating ML-004 for treatment of social communication deficit and/or irritability in autism spectrum disorder. The trial did not meet its primary endpoint. The Company intends to engage with FDA in an end-of-Phase 2 meeting to determine next steps, including potential strategic collaborations.
Phase 2 trial failure for ML-004 is a negative clinical development outcome that may affect future pipeline value. - Vanderbilt License Agreement Amendment
In September 2026, the Company entered into an amendment to the Vanderbilt Agreement. The amendment required a one-time payment of $0.4 million, revised certain development milestones, reduced aggregate milestone payment obligations from $52.4 million to up to $52.0 million, and revised sublicensing revenue sharing terms with percentages ranging from 2% to 50% depending on development stage at sublicense grant.
Amendment modifies milestone obligations and sublicensing terms; $0.4 million payment was accrued and paid in October 2026. - South San Francisco Lease
In June 2026, the Company entered into a 7-year lease for office and laboratory space in South San Francisco, California, with an option to extend for an additional 5 years. The lease has not yet commenced; expected to begin May 2027 subject to landlord tenant improvements. Total lease payments from October 2026 through end of lease term total $13.4 million.
New lease commitment represents future contractual obligation of $13.4 million; reflects Company's expansion of facilities. - Redwood City Lease Early Termination
In June 2026, the Company exercised the early termination option for its Redwood City, California lease, providing required 15-month notice to the lessor. The lease end date changed from June 2031 to September 2027. During the nine months ended September 30, 2026, the Company derecognized a right-of-use asset and lease liabilities of $3.4 million due to the term change.
Early termination reduces long-term lease obligations but results in non-cash derecognition charge; lease payments through September 2027 total $1.0 million.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MPLT in real time
Get material earnings, filing, IR, and earnings-call alerts by email.